Physician profile
Robert J Wallace
NPI 1821396151
$143,855.14
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $63K · 2020: $31K · 2021: $7,556 · 2022: $12K · 2023: $11K · 2024: $7,223 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Food and Beverage: $7,778 · Travel and Lodging: $2,634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,725.00 |
| Food and Beverage | $7,777.65 |
| Travel and Lodging | $2,633.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $130,331.56 | 2019-2025 | Mavyret |
| Viiv Healthcare Company | $4,514.14 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Gilead Sciences, INC. | $2,777.60 | 2019-2025 | Yeztugo, Biktarvy |
| Novo Nordisk INC | $1,198.80 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Theratechnologies INC. | $1,092.82 | 2019-2025 | Trogarzo, Egrifta |
| Astrazeneca Pharmaceuticals LP | $864.52 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Janssen Biotech, INC. | $806.73 | 2019-2023 | Symtuza |
| Merck Sharp & Dohme LLC | $557.19 | 2019-2024 | Delstrigo, Pifeltro, Dificid |
| Janssen Products, LP | $361.96 | 2019-2023 | Symtuza |
| Napo Pharmaceuticals INC | $270.40 | 2020-2025 | Mytesi |
| Emd Serono, INC. | $215.98 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $138.41 | 2020-2024 | Xifaxan |
| Bioness INC | $115.46 | 2020 | |
| Amarin Pharma, INC. | $91.15 | 2020-2021 | |
| Amgen INC. | $75.35 | 2025 | Repatha |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $74.00 | 2024-2025 | Ingrezza |
| Evoke Pharma, INC. | $46.14 | 2020-2021 | |
| Hologic Sales and Service, LLC | $45.05 | 2024 | Thinprep 2000 Processor, Aptima |
| Lilly USA, LLC | $38.92 | 2024-2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $38.79 | 2025 | Cologuard Collection Kit |
| Verity Pharmaceuticals INC. | $32.16 | 2025 | Tlando |
| Abbott Laboratories | $23.98 | 2025 | Freestyle Libre 2 |
| Tolmar, INC. | $22.48 | 2025 | Jatenzo |
| Glaxosmithkline, LLC. | $20.85 | 2021 | |
| Ucb, INC. | $20.40 | 2025 | Bimzelx |
| Teva Pharmaceuticals USA, INC. | $20.30 | 2025 | Austedo Xr |
| Genentech USA, INC. | $16.84 | 2021 | |
| Pfizer INC. | $15.26 | 2024 | |
| Supernus Pharmaceuticals, INC. | $14.54 | 2024 | Qelbree |
| Bausch Health US, LLC | $13.36 | 2024 | Aplenzin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.